BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therap
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2016.Cataloged from PD...
Incorporation of the tyrosine kinase inhibitor (TKI) imatinib in the frontline treatment of Philadel...
BACKGROUND: Compared with imatinib, nilotinib is a potent breakpoint cluster region/v-abl Abelson ...
BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leuke...
Imatinib mesylate (IM) has been demonstrated to be permissive for the emergence of T cells directed ...
Although the emergence of bone marrow (BM)-resident (p190)BCR-ABL-specific T lymphocytes has been co...
Recent studies by our groups have demonstrated the presence of BM-homing, BCR-ABL specific cytotoxic...
Blinatumomab is a bispecific anti-CD3 and anti-CD19 antibody that acts as a T-cell engager: by bindi...
Seven Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in first compl...
Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been repor...
There are several lines of evidence that T cells in patients with Multiple Myeloma (MM) and B-cell C...
Although the graft-versus-leukemia effect of allogeneic bone marrow transplantation (BMT) is of para...
Retention of CD34þ CML stem/progenitor cells during imatinib treatment and rapid decline after treat...
Background: Tyrosine Kinase Inhibitors (TKI) have been shown to be very effective for the treatment ...
Specifically targeting the oncogenic proteins that cause cancers is a rapidly growing field of labor...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2016.Cataloged from PD...
Incorporation of the tyrosine kinase inhibitor (TKI) imatinib in the frontline treatment of Philadel...
BACKGROUND: Compared with imatinib, nilotinib is a potent breakpoint cluster region/v-abl Abelson ...
BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leuke...
Imatinib mesylate (IM) has been demonstrated to be permissive for the emergence of T cells directed ...
Although the emergence of bone marrow (BM)-resident (p190)BCR-ABL-specific T lymphocytes has been co...
Recent studies by our groups have demonstrated the presence of BM-homing, BCR-ABL specific cytotoxic...
Blinatumomab is a bispecific anti-CD3 and anti-CD19 antibody that acts as a T-cell engager: by bindi...
Seven Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in first compl...
Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been repor...
There are several lines of evidence that T cells in patients with Multiple Myeloma (MM) and B-cell C...
Although the graft-versus-leukemia effect of allogeneic bone marrow transplantation (BMT) is of para...
Retention of CD34þ CML stem/progenitor cells during imatinib treatment and rapid decline after treat...
Background: Tyrosine Kinase Inhibitors (TKI) have been shown to be very effective for the treatment ...
Specifically targeting the oncogenic proteins that cause cancers is a rapidly growing field of labor...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2016.Cataloged from PD...
Incorporation of the tyrosine kinase inhibitor (TKI) imatinib in the frontline treatment of Philadel...
BACKGROUND: Compared with imatinib, nilotinib is a potent breakpoint cluster region/v-abl Abelson ...